NCT03859830 - Clinical Observation of the Performance of Artis Dialysis System, ArtiSet PrePost and Ultra HDF Line in Treatments of Patients With End-Stage Renal Disease (ESRD) | Biotech Hunter

Enrollment

276

Participants

Timeline

Start Date

January 22, 2019

Primary Completion Date

November 9, 2019

Study Completion Date

November 9, 2019

Conditions

End-Stage Renal Disease

Interventions

DEVICE

Artis Dialysis System, ArtiSet PrePost and Ultra HDF Line

The HDF session will be performed in post-dilution volume-controlled mode, with a minimum target total convective volume (VCtot) of 16 L and blood flow rate (QB) set at 200-300 mL/min.

DEVICE

AK200 Ultra S, extracorporeal circulation conduct of blood purification

The HDF session will be performed in post-dilution volume-controlled mode, with a minimum target total convective volume (VCtot) of 16 L and blood flow rate (QB) set at 200-300 mL/min.

Trial Locations (7)

100730

Investigational Site, Beijing

110001

Investigational Site, Shenyang

210009

Investigational Site, Nanjing

310003

Investigational Site, Hangzhou

325003

Investigational Site, Wenzhou

430060

Investigational Site, Wuhan

528000

Investigational Site, Foshan

All Listed Sponsors

collaborator

Baxter Healthcare Corporation

INDUSTRY

lead

Vantive Health LLC

INDUSTRY